Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. | Yamashita et al. Radiation Oncology 2010 5 32 http content 5 1 32 RADIATION ONCOLOGY RESEARCH Open Access Prescreening based on the presence of CT-scan abnormalities and biomarkers KL-6 and SP-D may reduce severe radiation pneumonitis after stereotactic radiotherapy Hideomi Yamashita Shino Kobayashi-Shibata AtsuroTerahara Kae Okuma Akihiro Haga Reiko Wakui Kuni Ohtomo and Keiichi Nakagawa Abstract Purpose To determine the risk factors of severe radiation pneumonitis RP after stereotactic body radiation therapy SBRT for primary or secondary lung tumors. Materials and methods From January 2003 to March 2009 SBRT was performed on 117 patients 32 patients before 2005 and 85 patients after 2006 with lung tumors primary 74 patients and metastatic recurrent 43 patients in our institution. In the current study the results on cases with severe RP grades 4-5 were evaluated. Serum Krebs von den Lungen-6 KL-6 and serum Surfactant protein-D SP-D were used to predict the incidence of RP A shadow of interstitial pneumonitis IP on the CT image before performing SBRT was also used as an indicator for RP. Since 2006 patients have been prescreened for biological markers KL-6 SP-D as well as checking for an IP-shadow in CT. Results Grades 4-5 RP was observed in nine patients after SBRT and seven of these cases were grade 5 in our institution. A correlation was found between the incidence of RP and higher serum KL-6 SP-D levels. IP-shadow in patient s CT was also found to correlate well with the severe RP. Severe RP was reduced from before 2005 to after 2006 p . There was no correlation between the dose volume histogram parameters and these severe RP patients. Conclusion Patients presenting with an IP shadow in the CT and a high value of the serum KL-6 SP-D before SBRT treatment developed severe radiation pneumonitis at a high rate. The reduction of RP incidence in patients treated after 2006 may have been attributed to prescreening of the .
